



Extended Abstract

Challenges and Controversies in the Diagnosis of MRONJ[†]

Olga Di Fede * and Giuseppina Campisi

Department of Surgical, Oncological and Oral Sciences, University of Palermo, 90133 Palermo, Italy; campisi@odonto.unipa.it

* Correspondence: odifede@odonto.unipa.it

† Presented at the XV National and III International Congress of the Italian Society of Oral Pathology and Medicine (SIPMO), Bari, Italy, 17–19 October 2019.

Published: 11 December 2019

Medication-related osteonecrosis of the jaw (MRONJ) is a relatively rare but potentially serious and debilitating complication. It consists of progressive bone destruction in the maxillofacial area of patients exposed to the treatment with drugs associated with the risk of ONJ (antiresorptive and antiangiogenic agents), in the absence of a previous radiation treatment [1].

In order to adjudicate MRONJ case, many considerations are essential for the clinician.

Firstly, in absence of bone exposure and or fistula, other signs or symptoms (e.g., abscess, periodontal instability, presence of swelling and/or pus, severe pain, lockjaw, sequestrum) are not diagnosed. This is due to restricted criteria of AAOMS definition in which these clinical findings are not included but already recognized and reported in literature [2–4].

Furthermore, many times the clinical history of the patient is not complete and all identified and reported drugs related to ONJ are not identified from the dentist, the practitioner, or the oncologist. Many clinicians take in account only bisphosphonates as drugs related to ONJ risk. Nowadays, many other drugs have been related to this adverse event, from antiresorptive to antiangiogenic agents (e.g., Bisphosphonates, Denosumab, Bevacizumab, Sunitinib). The lack of knowledge and the necessity of a continuous update is an essential element for all clinicians.

After, other critical point for MRONJ diagnosis is the disclaimer of imaging whereas this is essential for unexposed clinical form of osteonecrosis. The adding of radiological findings in case of suspicious of MRONJ determine not also an underestimation of frequency data but also a delay for staging and management [5,6].

It is important to note that in few years, many data are added to the definition of MRONJ and, probably, much more should be discovered. This is the main controversy in terms of diagnosis. The uniformity in terms of clinical and radiological findings must be achieved in short time since the underestimation and delay diagnosis have to avoid in order to support the affected patient, already overloaded from primary disease (i.e., cancer).

The main challenge is to create a multidisciplinary network for a standardized approach, with a sustained dialogue among specialists involved, should be always adopted in order to improve the efficacy of diagnosis process and to ameliorate the patient's quality of life

References

1. Di Fede, O.; Panzarella, V.; Mauceri, R.; Fusco, V.; Bedogni, A.; Lo Muzio, L.; Board, S.O.; Campisi, G. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. *BioMed Res. Int.* **2018**, 1–10, doi:10.1155/2018/2684924.
2. Fusco, V.; Santini, D.; Armento, G.; Tonini, G.; Campisi, G. Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: New horizons in oncology. *Expert Opin. Drug Saf.* **2016**, 15, 925–935, doi:10.1080/14740338.2016.1177021.

3. Ruggiero, S.L.; Dodson, T.B.; Fantasia, J.; Goodday, R.; Aghaloo, T.; Mehrotra, B.; O’Ryan, F. American Association of Oral and Maxillofacial Surgeons, American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. *J. Oral Maxillofac. Surg.* **2014**, *72*, 1938–1956, doi:10.1016/j.joms.2014.04.031.
4. Fedele, S.; Bedogni, G.; Scoletta, M.; Favia, G.; Colella, G.; Agrillo, A.; Bettini, G.; Di Fede, O.; Oteri, G.; Fusco, V.; et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. *Br. J. Oral Maxillofac. Surg.* **2015**, *53*, 13–17, doi:10.1016/j.bjoms.2014.09.001.
5. Migliario, M.; Mergoni, G.; Vescovi, P.; Martino, I.; Alessio, M.; Benzi, L.; Renò, F.; Fusco, V. Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition. *Dent. J.* **2017**, *5*, 13, doi:10.3390/dj5010013.
6. Bedogni, A.; Fedele, S.; Bedogni, G.; Scoletta, M.; Favia, G.; Colella, G.; Agrillo, A.; Bettini, G.; Di Fede, O.; Oteri, G.; et al. Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. *Br. J. Oral Maxillofac. Surg.* **2014**, *52*, 603–608, doi:10.1016/j.bjoms.2014.04.009.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).